Follow Our Live Coverage of COVID-19 Developments

Study Compares Anticoagulants for Antiphospholipid Syndrome

Authors find rivaroxaban not noninferior to vitamin K antagonists for secondary thromboprophylaxis

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

TUESDAY, Oct. 15, 2019 (HealthDay News) -- In thrombotic antiphospholipid antibody syndrome (APS), rivaroxaban is not noninferior to dose-adjusted vitamin K antagonists (VKAs), according to a study published online Oct. 15 in the Annals of Internal Medicine.

Josep Ordi-Ros, M.D., Ph.D., from the Vall d'Hebrón Research Institute in Barcelona, Spain, and colleagues conducted a three-year noninferiority trial at six university hospitals in Spain. A total of 190 adults with thrombotic APS were randomly assigned to rivaroxaban or dose-adjusted VKAs.

The researchers found that recurrent thrombosis occurred in 11.6 and 6.3 percent of patients in the rivaroxaban and VKA groups, respectively, after three years of follow-up (risk ratio in the rivaroxaban group, 1.83; 95 percent confidence interval, 0.71 to 4.76). Stroke occurred more often in patients receiving rivaroxaban versus VKAs (nine versus zero events; corrected risk ratio, 19.00; 95 percent confidence interval, 1.12 to 321.9). Major bleeding occurred in 6.3 and 7.4 percent of patients in the rivaroxaban and VKA groups, respectively (risk ratio, 0.86; 95 percent confidence interval, 0.30 to 2.46). Rivaroxaban-treated patients with previous arterial thrombosis, livedo racemosa, or APS-related cardiac valvular disease were more likely to have an increased risk for recurrent thrombosis.

"The primary efficacy analyses could not demonstrate rivaroxaban noninferiority to dose-adjusted VKAs," the authors write. "In fact, although inconclusive, we found an increased risk for recurrent thrombosis in the rivaroxaban group, with a predominance of arterial thrombotic events and stroke in particular."

Several authors disclosed financial ties to pharmaceutical companies, including Bayer Hispania, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Last Updated: